PDCD1 and skin squamous cell carcinoma: Over the last few years, anti–PD-1 agents including cemiplimab and pembrolizumab have become the standard systemic therapy for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) that is considered incurable with surgery or radiation alone.1